Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — Q4 2025 Earnings Presentation
6 slides from Vitrolife Ab's earnings presentation, 2025
Slide 1: Pre-silent call prior to Q4 2025
Vitrolife AB (publ) Pre-silent call prior to Q4 2025 Bronwyn Brophy O'Connor, CEO Pär Ihrskog, CFO Amelie Wilson, Investor relations, external corporate communications and executive support
Slide 2: Genetic services restructuring program and goodwill impairment
Vitrolife announces genetic services restructuring program targeting annualised savings of 65 MSEK and recognises a 5.4 BSEK goodwill impairment • Vitrolife conducts a strategic review of its genetic services portfolio and markets. • Decided to: -discontinue two genetic test lines (GPDx and NACE) -e
Slide 3: Key factors to consider in Q4 2025
Key factors to consider in Q4 2025 1. Strong comparable figures 2. IVF Executive order 3. APAC cycle growth Update from the White house in Very little signs of recovery in Strong growth of Consumables the beginning of Q4 2025. Asia. and Technologies in Q4 2024. A slow steady pick up in IVF cycles. De
Slide 4: 1. Strong comparable figures
1. Strong comparable figures Strong net sales in Q4 2024 driven by high Consumables and Technologies revenue. Strong gross profit and EBITDA margins due to the product and market mix and we also had a regional mix benefit in Q4 2024. 4
Slide 5: Reasons to invest in Vitrolife AB (publ)
Reasons to invest in Vitrolife AB (publ) • Underlying resilient market growth. • High quality brands linked with outstanding service and support. • Proven track record of profitable growth. • Innovation and technology leader within fertility. • Ambitious strategy and long-term objectives. Contact: in
Slide 6: Disclaimer
Disclaimer This presentation may contain estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there